Jones Financial Companies
JSPR icon

Jones Financial Companies’s Jasper Therapeutics JSPR Stock Holding History

Jones Financial Companies’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$53 Hold
50
– – ﹤0.01% 4669
2025
Q4 		$92 Hold
50
– – ﹤0.01% 4321
2025
Q3 		$124 Buy
+50
New +$152 ﹤0.01% 4151

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Jones Financial Companies's JSPR Position: Q1 2026 in Review

Jones Financial Companies held its Jasper Therapeutics (JSPR) position steady in Q1 2026 at 50 shares worth $53. The position accounts for ﹤0.01% of the portfolio, ranked #4669.

Jones Financial Companies first reported a position in JSPR in Q3 2025 and has held it in 3 quarters since. The position peaked at $124 in Q3 2025. 58 funds tracked by Wall St. Rank hold JSPR as of Q1 2026.

  • Jones Financial Companies held 50 shares of Jasper Therapeutics worth $53 as of Q1 2026.
  • Jones Financial Companies left its Jasper Therapeutics share count unchanged in Q1 2026.
  • Jasper Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q1 2026, its #4669 holding.
  • Jones Financial Companies first reported a position in Jasper Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Jones Financial Companies's Jasper Therapeutics position peaked at $124 in Q3 2025.
  • 58 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2026.

Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.